Pure Global

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) - Trial NCT06140836

Access comprehensive clinical trial information for NCT06140836 through Pure Global AI's free database. This Phase 3 trial is sponsored by Bristol-Myers Squibb and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 230 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06140836
Phase 3
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06140836
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

Study Focus

Repotrectinib

Interventional

drug

Sponsor & Location

Bristol-Myers Squibb

Augusta,New York,New York,Buenos Aires,São José do Rio Preto,São Paulo,Montréal,Santiago,Santiago,Zhengzhou,Wuhan,Nanchang,Jinan,Linyi,Kunming,Hangzhou,Köln,Mainz,Budapest,Aviano,Nagoya,Kashiwa,Matsuy, Argentina,Brazil,Canada,Chile,China,Germany,Hungary,Italy,Japan,Romania,Turkey,United States of Amer

Timeline & Enrollment

Phase 3

Jan 15, 2024

Jan 27, 2031

230 participants

Primary Outcome

Progression-free Survival (PFS) as per Blinded Independent Central Review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

Summary

The purpose of this study is to evaluate the efficacy and safety of repotrectinib and
 crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive
 non-small cell lung cancer (NSCLC).

ICD-10 Classifications

Carcinoma in situ: Bronchus and lung
Secondary malignant neoplasm of lung
Malignant neoplasm: Lower lobe, bronchus or lung
Malignant neoplasm: Bronchus or lung, unspecified
Malignant neoplasm of bronchus and lung

Data Source

ClinicalTrials.gov

NCT06140836

Non-Device Trial